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Abstract
In laboratory medicine, several studies have described the most frequent errors in the different phases of the total testing process, and a large pro-
portion of these errors occur in the pre-analytical phase. Schemes for registration of errors and subsequent feedback to the participants have been 
conducted for decades concerning the analytical phase by External Quality Assessment (EQA) organizations operating in most countries. The aim of 
the paper is to present an overview of different types of EQA schemes for the pre-analytical phase, and give examples of some existing schemes. 
So far, very few EQA organizations have focused on the pre-analytical phase, and most EQA organizations do not offer pre-analytical EQA schemes 
(EQAS). It is more difficult to perform and standardize pre-analytical EQAS and also, accreditation bodies do not ask the laboratories for results from 
such schemes. However, some ongoing EQA programs for the pre-analytical phase do exist, and some examples are given in this paper. The met-
hods used can be divided into three different types; collecting information about pre-analytical laboratory procedures, circulating real samples to 
collect information about interferences that might affect the measurement procedure, or register actual laboratory errors and relate these to quality 
indicators. These three types have different focus and different challenges regarding implementation, and a combination of the three is probably 
necessary to be able to detect and monitor the wide range of errors occurring in the pre-analytical phase.
Key words: quality assurance, health care; pre-analytical; quality indicators, health care; external quality assessment
Received: November 11, 2013 Accepted: January 03, 2014
How to conduct External Quality Assessment Schemes for the pre-analytical 
phase?
Gunn B.B. Kristensen1*, Kristin Moberg Aakre1,2, Ann Helen Kristoffersen2,3, Sverre Sandberg2,3
1The Norwegian EQA Program (NKK), Bergen, Norway
2Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway
3Noklus (Norwegian Centre for Quality Improvement of Primary Care Laboratories), University of Bergen, Bergen, Norway
*Corresponding author: gunn.kristensen@noklus.no
Review
Introduction
In laboratory medicine, several studies have de-
scribed the most frequent errors in the different 
phases of the total testing process (TTP) (1-12), and 
a large proportion of these errors occur in the pre-
analytical phase (2,5,13-17).
The first step in improving the quality of the pre-
analytical phase is to describe potential errors and 
to try to estimate which errors are most dangerous 
for the outcome of the patient (13,18-22). Existing 
pre-analytical procedures should be compared to 
existing recommendations and thereafter im-
proved to minimize the risk of errors. In addition, 
the frequency of errors should be recorded on a 
regular basis to detect improvement or deteriora-
tion over time, and further to explore if procedures 
should be changed.
Schemes for recording of errors and subsequent 
feedback to the participants have been conducted 
for decades concerning the analytical phase by Ex-
ternal Quality Assessment (EQA) organizations op-
erating in most countries. It is reasonable that 
these organizations also take upon them to set up 
EQA Schemes (EQAS) for the pre-analytical phase. 
At present, however, most EQA organizations do 
not offer such schemes. An important challenge, 
when developing EQAS for the extra-analytical 
phases, is the variety of locations and staff groups 
involved in the total testing process, of which sev-
eral are outside the laboratory’s direct control. Test 
ordering, data entry, specimen collection/handling 
and interpretation of results often involve other 
than laboratory staff. Some of the pre-analytical 
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schemes, e.g. schemes on test ordering, could also 
involve other health care professionals. The con-
tact and communication between the clinicians/
nurses and the laboratory staff is often limited 
(7,23). The ISO 15189: 2012 states that “External 
quality assessment programs should, as far as pos-
sible, provide clinically relevant challenges that 
mimic patient samples and have the effect of 
checking the entire examination process, includ-
ing pre- and post-examination procedures” (item 
5.6.4) (24). To our knowledge, and in contrast to 
what is required for the analytical phase, accredi-
tation bodies do not ask laboratories for results 
from EQAS regarding the pre-analytical phase. If 
this is changed, it will be a driver for the EQA orga-
nizations to set up such schemes, and for the par-
ticipants to use them. Consequently, a joint effort 
between EQA organizations, accreditation bodies 
and clinical laboratories seems necessary to imple-
ment pre-analytical EQA schemes. The aim of this 
paper is to present an overview of different types 
of EQA schemes for the pre-analytical phase and 
to give examples of existing schemes.
How to perform a pre-analytical EQA 
scheme?
Fortunately, EQAS for the pre-analytical phase are 
increasingly being developed, and roughly three 
different methods have been conducted:
Type I:•	  Registration of procedures: Circulation 
of questionnaires asking about procedures on 
the handling of certain aspects of the pre-ana-
lytical phase, e.g. how “sample stability” or tube 
filling are dealt with, which criteria are used for 
sample rejection, and how these issues are 
communicated to the requesting physicians.
Type II:•	  Circulation of samples simulating er-
rors: For example distribution of real samples 
with matrixes or samples with contamination 
which might interfere with the measurement 
procedures. This is similar to usual analytical 
EQAS, since a sample is sent to the laboratories. 
Case histories can be sent together with the 
sample to elucidate how these samples are 
dealt with, and how the results are communi-
cated to the physicians.
Type III:•	  Registration of errors/adverse events: 
The incidences of certain types of pre-analytical 
errors (some of them could be quality indica-
tors (QIs)) are registered and reported by the 
laboratories to the EQA organizer.
The EQA organizer should as usual provide feed-
back reports for the participating laboratories, en-
abling the laboratories to compare their results 
with the other participants. In addition, the feed-
back reports should include advice on how to min-
imize errors. In case of error reporting (Type III), the 
EQA organizer should also lead the harmonization 
of QIs for a valid comparison of error rates between 
different locations. Examples of the three different 
methods to conduct pre-analytical EQAS will be 
given below. Ongoing EQAS are summarized in Ta-
ble 1.
Type I: Registration of procedures
Identification and registration of pre-analytical 
procedures can be performed by circulating ques-
tionnaires, with open or multiple choice questions. 
Case histories to illustrate the potential conse-
quences of pre-analytical errors for the patients 
may be included. A clear advantage of this type of 
EQAS is the limited resources needed for distribut-
ing and completing the scheme. Several aspects 
of the pre-analytical phase can be covered, and 
the questionnaire may potentially reach laborato-
ries all over the world in a short time using an elec-
tronic contact and report form.
The Norwegian EQA program (NKK) has developed 
a pre-analytical EQA scheme which aims to identi-
fy especially problematic pre-analytical issues re-
lated to clinical chemistry analyses and hemostasis 
testing. This scheme is carried out by circulating 
web-based questionnaires (mostly multiple choice 
questions) to the Norwegian laboratories once a 
year dealing with different aspects of the pre-ana-
lytical phase. The laboratories receive a feedback 
report after each survey, showing their own re-
sults, the overall results and an overview of the rel-
evant recommended procedures from guidelines 
and recent studies. The three surveys performed 
so far (2011, 2012 and 2013) (Table 1), concluded 
that there is a large variability in several pre-ana-
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Method Pre-analytical issues studied Frequency Performed by
Type I . Registration of procedures 
Registration of procedures via 
web-based multiple choice 
questionnaire
Clinical chemistry: Hemolysis, stability of 
samples (2011)
1 x year
Norwegian Clinical Chemistry 
EQA program (NKK)
Not published
Hemostasis testing: Phlebotomy, sample 
handling and sample acceptance (2012)
Glucose: Sample handling and sample 
treatment (2013)
Registration of procedures via 
web-based multiple choice 
questionnaire
Hemostasis testing 2 x year ECAT/INSTAND 2011 (25)
Clinical case-based European EQAS 
covering pre-analytical, analytical 
and post-analytical phase. Five sets 
of multi-specimen samples
Porphyria: Case history based test ordering 2 x year
Norwegian Porphyria Centre 
(NAPOS)/The European 
Porphyria Network (EPNET
(26)
Registration of procedures via 
web-based multiple choice 
questionnaire
5 general pre- and post-analytical questions, 
5 questions within specific disciplines (i.e. 
coagulation, hematology, immunology, 
microbiology)
2 x year * Quality Control Center Switzerland (CSCQ)
Registration of procedures via 
multiple choice questionnaire Urine chemistry, clinical chemistry 4 x year * WEQAS
Registration of procedures via 
web-based multiple choice 
questionnaire
Hematology, sample handling 1 x year * INSTAND
Type II . Circulation of samples simulating errors
Circulate samples for extraction of 
RNA/DNA
Sample preparation for DNA and RNA 
testing 1 x year
SPIDIA-DNA, 2012
SPIDIA-RNA, 2011
European Commission (EC)
(33, 34)
Circulate samples Sample indicies – lipemic, icteric, hemolysis index 4 x year * WEQAS
Type III . Registration of errors/adverse events
Q-Track (since 1998, 1 x year, 
ongoing) programs, registration of 
error rates
Patient/sample identification, specimen 
handling/preparation, specimen 
acceptability, customer satisfaction
4 x year College of American Pathologists (CAP) (39)
Registration of rejection of samples
Registration of the rejection rate and causes 
for rejecting the samples during 1 month or 
100 rejections
2 x year
Committee for the Quality 
of the Extra-analytical phase 
(started within The Spanish 
Society of Clinical Chemistry 
and Molecular Pathology 
(SEQC) in 1998 (41)
Registration of key incidents which 
represent either the most frequent 
or most serious incident
Patient identification, incorrect patient 
preparation, phlebotomy, sample 
preparation/handling and sample 
acceptability
4 x year
Key Incident Monitoring and 
Management Systems Quality 
Assurance (KIMMS QA) 2009 (43).
* Personal communication at the EQALM meeting in Bucuresti in 2013 where the participants were asked if they had any 
pre-analytical EQAS. Three EQA organizers replied: WEQAS (Annette Thomas, http://www.weqas.com/eqa/index.html) INSTAND 
(http://www.instandev.de), and CSCQ (Dagmar Kesseler, http://www.cscq.ch)
Table 1. Examples of ongoing pre-analytical EQAS.
http://dx.doi.org/10.11613/BM.2014.013 Biochemia Medica 2014;24(1):114–22 
  117
Kristensen GBB. et al. Quality Assurance for the pre-analytical phase
lytical practices and considerable room for im-
provement.
In 2009, the Croatian Chamber of Medical Bio-
chemists (CCMB) performed a survey in Croatian 
laboratories to investigate appropriateness of pro-
cedures in the extra-analytical phases and to de-
tect procedures most prone to errors of potentially 
clinical importance (27). A multiple choice ques-
tionnaire including pre-analytical conditions and 
criteria for sample acceptance and procedures of 
phlebotomy were circulated to members of CCMB. 
The study concluded that there is an urgent need 
for improving activities by appropriate recording 
and monitoring of the extra-analytical phases; em-
phasizing the importance of initiating pre- and 
post-analytical EQAS.
Labquality, the Finnish EQA organization, are about 
to start pre-analytical EQAS in 2014. The program 
will include case studies and multiple choice ques-
tionnaires concerning phlebotomy practices, pre-
analytical procedures for clinical chemistry, micro-
biology and for blood gas analyzers (Personal in-
formation from Jonna Pelanti, Labquality, FI).
Challenges regarding registration of 
procedures as pre-analytical EQAS
To avoid misinterpretations, the questionnaires 
used in EQAS should be validated by experts in 
the field and/or in pilot studies to a few laborato-
ries. This is especially important if the question-
naires are circulated in different countries and not 
translated into local languages. The questions 
should be designed to stimulate the participants 
to answer how the procedures really are per-
formed, and not how they ideally should be per-
formed (e.g. ask for written procedures). Providers 
of such schemes should also be aware that queu-
ing of answers (multiple choices) might influence 
the results. Standardized follow-up of the surveys 
should be performed by offering advises to the 
participants on how to improve their procedures.
Type II: Circulation of samples simulating 
errors
EQAS for the pre-analytical phase can be per-
formed using real samples with a matrix potential-
ly interfering with the measurement procedures, 
as for example hemolysed, lipemic, or icteric sam-
ples or samples containing drugs known to inter-
fere. Another example is to send the wrong sam-
ple material (e.g. serum instead of plasma). This 
type is in some instances comparable to analytical 
EQAS, since a sample is sent to the laboratories for 
measurement of pre-defined analytes. As for ana-
lytical EQAS, case histories can be included to elu-
cidate which pre-analytical procedures are per-
formed and how the results (or lack of results in 
case of sample rejection) are communicated to the 
physicians.
The feedback reports for these surveys are compa-
rable to feedback reports for regular EQA surveys, 
and should include a comparison of the laborato-
ry’s results to the results of all participants in addi-
tion to an overview of existing guidelines/recom-
mendations and recent publications.
Surveys focusing on problematic areas within the 
pre-analytical phase may not be suitable for regu-
lar schemes, but can be conducted as specialized 
pre-analytical EQAS performed once (or a couple 
of times). In this way, the EQAS organizer can 
choose to study the most relevant issue present. 
The Nordic committee for External Quality Assur-
ance Programmes in Laboratory Medicine (NQLM) 
carried out four different EQA interference surveys 
between 1999 and 2002 (28). The aim was to as-
sess the effects of hemolysed, icteric and lipemic 
samples on some common clinical chemistry se-
rum analyses. During 2014, a similar EQA survey 
will be performed in the Nordic countries to re-
ceive updated information on analytical perfor-
mance and handling of hemolysed samples.
One of the major goals of the newly started Euro-
pean Commission funded project SPIDIA (Stan-
dardization and improvement of generic pre-ana-
lytical tools and procedures for in-vitro diagnos-
tics) has been to develop evidence-based guide-
lines for the pre-analytical phase of blood samples 
used for molecular testing (29). The SPIDIA project 
has resulted in two pan-European EQAS focusing 
on the pre-analytical phase of DNA and RNA-based 
analyses (30,31) (Table 1). Blood samples were sent 
to the laboratories which performed DNA/RNA ex-
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traction of the material, the extracted material was 
returned, and the EQA organizer assessed the 
quality. The results of these surveys will provide 
the basis for performing new pan-European EQAS 
and further provide the basis for implementation 
of evidence-based guidelines for the pre-analyti-
cal phase of DNA and RNA analyses (29).
Challenges regarding the use of real samples 
in pre-analytical EQAS
The requirements for samples to be used in pre-
analytical EQAS are similar to the requirements for 
samples in analytical EQAS. The samples should 
be similar to native patient samples containing the 
actual interferences, and should be homogenous 
and stable during the survey period. Additionally, 
they should reflect actual poor pre-analytical con-
ditions like incorrect blood sampling and sample 
errors due to using tubes containing incorrect ad-
ditives (e.g. serum or EDTA when citrated plasma is 
required) or inappropriate specimen preparation, 
centrifugation, aliquoting, pipetting or sorting. 
Mimicking real life situations is a challenge when 
producing sample material in a large scale. Only a 
limited set of pre-analytical problems can be in-
vestigated by utilizing this method (Type II), and 
for some areas it seems natural to perform the 
EQAS once or on an irregular basis. One should 
also take into consideration the bias introduced if 
the participants know they are to receive a sample 
with an interfering substance (participating in a 
pre-analytical scheme), and it might therefore be 
better to contaminate samples in a regular EQA 
scheme.
Type III: Registration of errors/adverse 
events
EQAS for the pre-analytical phase can be per-
formed by initiating registration of defined and 
standardized types of errors (or adverse events). 
The error rate (or the rate of adverse events) dur-
ing a pre-specified time interval should then be re-
ported to the EQA organization. Systematic regis-
tering of incidents may point out bottle necks and 
indicate which areas are most error-prone (32). An 
accredited laboratory must have a system for reg-
istration of incidents and are required to establish 
QIs as a measure of the laboratory’s performance 
(ISO 15189) (24). Utilizing this system in an EQA 
program (e.g. the EQA provider suggest QIs to the 
laboratories; the laboratories thereafter report 
their QI data to the EQA provider, making compari-
son between laboratories regarding QI perfor-
mances possible) is perhaps the best EQA program 
for monitoring pre-analytical (and post-analytical) 
errors. The QIs found most appropriate should also 
be harmonized between EQA organizers.
The participants should receive a feedback report 
showing their own QI performance compared to 
the results of all participants and to desirable qual-
ity specifications. It should also include historical 
data showing the development of the perfor-
mance of the laboratory’s QIs.
In 1989, the College of American Pathologists (CAP) 
started the Q-Probe program, carried out as time-
limited studies lasting 1-4 months, to define criti-
cal performance measures in laboratory medicine, 
describe error rates on these measures and pro-
vide suggestions to decrease the error rate (33,34). 
In 1998, CAP developed this concept further and 
started the ongoing Q-Track program (33) (Table 
1). Data is collected according to defined methods 
and time frames by utilizing standardized forms. 
CAP provides a quarterly “Performance Manage-
ment Report” package which helps the laborato-
ries to identify issues providing the opportunity 
for improvement and to monitor the effect of 
changes. So far, information on error rates from 
more than 130 worldwide inter-laboratory studies 
has been included in CAP’s databases (34). The er-
ror rate has been determined for almost all the im-
portant steps of the total testing process, QIs have 
been established, and suggestions for error reduc-
tion provided. Improvement can be quantified as 
exemplified by one of the most frequently occur-
ring errors; missing wristbands, where the median 
error rate was reduced from more than 4% to less 
than 1% during four years (35). Similarly, partici-
pants who participated for two years demonstrat-
ed a significant declining trend in sample rejection 
rate (36).
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The Spanish Society of Clinical Chemistry and Mo-
lecular Pathology (SEQC) has since 1998 conduct-
ed two EQAS per year, registering rejections of 
samples and the causes for rejections (Table 1). A 
retrospective analysis of 10 surveys (2001-2005) 
summarized and evaluated the data and conclud-
ed that “specimen lost or not received” (37.5%), 
“hemolysis” (29.3%) and “clotted samples” (14.4%), 
were the main causes for sample rejection (37). 
The percentage of sample rejections was highest if 
the samples were collected in wards outside the 
central laboratory. The retrospective evaluation of 
the program resulted in a simplified scheme as 
some of the included variables (e.g. type of serum 
tubes (gel, silicone or no separator), type of antico-
agulant employed (liquid or solid), extraction pro-
cedure (with or without vacuum) and material em-
ployed (glass or plastic device)) turned out to be 
irrelevant.
The results from an EQAS performed by Australian 
chemical pathology laboratories, aiming at mea-
suring transcription (defined as any instances 
where the data on individual request forms were 
not identical to the data entered into the labora-
tory’s computer system, e.g. patient identification, 
patient sex and age, patient ward location or ad-
dress, tests requested and requesting doctor iden-
tification) and analytical errors, have been summa-
rized (38). This study showed a large inter-labora-
tory variation in total error rates (5 to 46%). The 
maximum error rates detected were 39% and 26% 
for transcription and analytical errors, respectively. 
The study concluded that there is a need to estab-
lish broader quality assurance programs and per-
formance requirements for the pre-analytical 
phase.
Several pilot EQA-schemes were performed dur-
ing 2006-2009 throughout Australia and New Zea-
land, and the experiences from these surveys were 
used to make the current “Key Incident Monitoring 
and Management Systems Quality Assurance” 
(KIMMS QA) program (39) (Table 1). In this scheme, 
the participating laboratories are asked to register 
a subset of pre- and post-analytical (PAPA) inci-
dents, which represents either the most frequent 
or the most serious incidents, or which represents 
incidents with the greatest opportunity for inter-
laboratory benchmarking and improvement. The 
data from the participants is pooled to form a na-
tional frequency distribution of PAPA incidents, 
and each participating laboratory can compare 
their own results with this distribution. For 70% of 
all reported incidents, the root causes require in-
teraction between the laboratory staff and other 
health care workers. In the last KIMMS EQA survey, 
the overall PAPA incident rate was 1.22% and the 
most frequent incident was inadequate patient or 
sample identification (0.28%) (39).
As a part of a project to reduce errors in laboratory 
testing, the IFCC Working Group on Laboratory er-
rors and patient safety (WG-LEPS) aimed to devel-
op a series of QIs, specially designed for clinical 
laboratories (40,41). The aim of the project is to 
provide a common framework and to establish a 
set of harmonized QIs which should cover all steps 
of the TTP. The group concluded that a model of 
QIs managed as an EQAS can serve as a tool to 
monitor and control the pre-, intra- and post-ana-
lytical activities. The QIs suggested by WG-LEPS 
were evaluated in a study performed during 2009 
and 2011. The results showed that QIs in the ana-
lytical phase improved much more than the corre-
sponding for the extra-analytical phases, probably 
because improvement in the extra-analytical phas-
es may be more complex requiring close coopera-
tion between the laboratory staff and the health 
care workers outside the laboratory (42). This find-
ing indicates that measurement of errors alone will 
not reduce the error rates, but corrective actions 
which include cooperation, teamwork and firm 
follow-up on achievements are necessary.
In a recent study performed in a group of clinical 
laboratories in Catalonia (Spain), the results ob-
tained for the QIs of key processes were analyzed 
over a five years period (2004-2008) (43). The ob-
jective was to determine the QI evolution, identify 
processes requiring corrective measures, and ob-
tain robust performance specifications. Different 
indicators were evaluated according to efficiency 
and safety. The average yearly inter-laboratory me-
dian value for the different indicators over the five 
years period was used as the desirable specifica-
tion for the indicators. The values obtained were 
transformed to the Six Sigma scale and processes 
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with sigma values ≥ 4, were considered well con-
trolled (44). The medians for most QIs were consid-
ered stable during the study period, however, if 
the sigma value was less than 4 the QIs were con-
sidered robust but subject to improvement. Exam-
ples of pre-analytic processes outside the labora-
tory that could be improved were “Total incidenc-
es in test requests” (sigma 3.4) and “Patient data 
missing” (sigma 3.4). Within the laboratory “Unde-
tected requests with incorrect patient name” ob-
tained the lowest sigma value (2.9). The method 
used in this study could also be performed as a 
regular EQA scheme for the pre-analytical phase.
Challenges regarding the use of QIs managed 
as an EQAS
The EQA organization should develop QIs and dis-
tribute registration systems to the laboratories, 
and this may be a quite labor intensive process. 
Harmonization is of uttermost importance, since 
variation in the methods used to register the er-
rors might influence the results and make compar-
ison between laboratories difficult. Harmonization 
of QIs may be difficult on an international basis if 
laboratory practices differ between regions, but 
harmonization within local areas should be possi-
ble. A challenge for the participating laboratories 
is the extra resources (time and personnel) needed 
to register their own errors. It is extremely impor-
tant to focus on improving the system and not fo-
cus on each individual, since this might lead to un-
der-reporting of errors. Most errors in laboratory 
medicine are classified as blameless and represent 
the accumulation of a number of contributing 
events, indicating the need to modify systems as 
opposed to disciplining individuals (32,45).
Conclusion
So far, very few EQA organizations have focused 
on the pre-analytical phase, compared to the ana-
lytical phase, even if the pre-analytical phase is 
more prone to errors. In this paper, three different 
types of pre-analytical EQAS are described, having 
somewhat different focus and different challenges 
regarding implementation. A combination of the 
three is probably necessary to be able to detect 
and monitor the wide range of errors occurring in 
the pre-analytical phase. It might be a good idea 
to start with pre-analytical EQA schemes national-
ly since they are easier to adapt to local conditions 
and results could be discussed on local users meet-
ings. Based on the results of these schemes one 
could in co-operation with other countries devel-
op international schemes aiming at harmonizing 
pre-analytical guidelines and QIs. Pre-analytical 
EQA schemes of type II will in many instances be 
size-restricted by the supply of EQA sample mate-
rial, while type I and III might be more suitable for 
international cooperation through international 
EQA organizations (e.g. EQALM). Development of 
pre-analytical EQA schemes and publication of the 
results should be encouraged since information of 
such schemes and their ability to improve pre-an-
alytical routines in the laboratories are scarce in 
the literature.
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